| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 2,070 | 1,460 | 1,440 | 0 | 0 |
| Sales Growth | +41.78% | +1.39% | unch | unch | unch |
| Net Income | -94,900 | -87,610 | -81,050 | -78,330 | -16,190 |
| Net Income Growth | -8.32% | -8.09% | -3.47% | -383.82% | -38.97% |
Fusion Pharmaceuticals Inc (FUSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing radiopharmaceuticals as precision medicines. The compnay's lead program includes FPI-1434, which is in clinical trial. Fusion Pharmaceuticals Inc. is based in Hamilton, Canada.
Fiscal Year End Date: 12/31